Literature DB >> 17224672

Updates in Acanthamoeba keratitis.

Shady T Awwad1, W Matthew Petroll, James P McCulley, H Dwight Cavanagh.   

Abstract

PURPOSE: Acanthamoeba keratitis is a potentially blinding microbial disease that has been increasing in incidence during the past two decades. Prognosis of this serious disease had been dismal, but improvement in diagnosis, a better understanding of the natural course of the disease, and recent introduction of multiple and effective therapeutic agents have resulted in improvement of visual outcomes.
METHODS: A review of literature pertaining to Acanthamoeba keratitis.
RESULTS: Contact lens wear and exposure to contaminated water sources remain the most important risk factors; however, in vivo confocal microscopy and improved biomicroscopic screening have proven instrumental in accurate early diagnosis. Complications of Acanthamoeba keratitis include dacryoadenitis, corneal melting and scarring, severe secondary glaucoma, cataract, and chronic anterior segment inflammation that can rarely lead to reactive blinding retinal ischemia. Combination chemotherapeutic agents have been shown to be more effective than monotherapy, whereas rehabilitative surgery such as penetrating keratoplasty is best performed on a quiet eye free of ocular inflammation and with no residual amoebae.
CONCLUSIONS: Increased suspicion by clinicians for Acanthamoeba and confocal microscopy have allowed more rapid and accurate diagnosis; treatment with multiple antiamoeba drugs is essential to disease resolution. Provided there are no residual amoebae after treatment, penetrating keratoplasty has been successful in visual rehabilitation. Secondary glaucoma occurs frequently and may require drainage procedures for control of intraocular pressure. Posterior complications are rare but may lead to ischemic retinitis.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17224672     DOI: 10.1097/ICL.0b013e31802b64c1

Source DB:  PubMed          Journal:  Eye Contact Lens        ISSN: 1542-2321            Impact factor:   2.018


  26 in total

Review 1.  Medical interventions for acanthamoeba keratitis.

Authors:  Majed Alkharashi; Kristina Lindsley; Hua Andrew Law; Shameema Sikder
Journal:  Cochrane Database Syst Rev       Date:  2015-02-24

2.  [Acanthamoeba keratitis].

Authors:  N Szentmáry; L Daas; P Matoula; S Goebels; B Seitz
Journal:  Ophthalmologe       Date:  2013-12       Impact factor: 1.059

Review 3.  Pathogenesis of acanthamoeba keratitis.

Authors:  Noorjahan Panjwani
Journal:  Ocul Surf       Date:  2010-04       Impact factor: 5.033

4.  Bacteriocin-like substance from Bacillus amyloliquefaciens shows remarkable inhibition of Acanthamoeba polyphaga.

Authors:  Lisianne Brittes Benitez; Karin Caumo; Adriano Brandelli; Marilise Brittes Rott
Journal:  Parasitol Res       Date:  2010-10-22       Impact factor: 2.289

Review 5.  Molecular phylogeny of acanthamoeba.

Authors:  Hyun Hee Kong
Journal:  Korean J Parasitol       Date:  2009-10       Impact factor: 1.341

6.  Clinical and histologic evaluations of experimental Acanthamoeba keratitis.

Authors:  Zubeyde Akin Polat; Semra Ozcelik; Ayse Vural; Esin Yildiz; Ali Cetin
Journal:  Parasitol Res       Date:  2007-08-14       Impact factor: 2.289

7.  Amoebicidal activities of alexidine against 3 pathogenic strains of acanthamoeba.

Authors:  Hassan Alizadeh; Sudha Neelam; H Dwight Cavanagh
Journal:  Eye Contact Lens       Date:  2009-01       Impact factor: 2.018

8.  Diagnosis of infections caused by pathogenic free-living amoebae.

Authors:  Bruno da Rocha-Azevedo; Herbert B Tanowitz; Francine Marciano-Cabral
Journal:  Interdiscip Perspect Infect Dis       Date:  2009-08-02

9.  Evaluation of three different methods to establish animal models of Acanthamoeba keratitis.

Authors:  Meiyu Ren; Xinyi Wu
Journal:  Yonsei Med J       Date:  2009-12-29       Impact factor: 2.759

10.  National outbreak of Acanthamoeba keratitis associated with use of a contact lens solution, United States.

Authors:  Jennifer R Verani; Suchita A Lorick; Jonathan S Yoder; Michael J Beach; Christopher R Braden; Jacquelin M Roberts; Craig S Conover; Sue Chen; Kateesha A McConnell; Douglas C Chang; Benjamin J Park; Dan B Jones; Govinda S Visvesvara; Sharon L Roy
Journal:  Emerg Infect Dis       Date:  2009-08       Impact factor: 6.883

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.